IYIsmail Yahaya

Ismail Yahaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ismail Yahaya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of osteoarthritis in lower middle- and low-income countries: a systematic review and meta-analysis

    by Ismail Yahaya, Tanya Wright, Opeyemi O. Babatunde, Nadia Corp, Toby Helliwell, Lisa Dikomitis, Christian D. Mallen

    Evidence from the Global Burden of Disease studies suggests that osteoarthritis (OA) is a significant cause of disability globally; however, it is less clear how much of this burden exists in low-income and lower middle-income countries. This study aims to determine the prevalence of OA in people living in low-income and lower middle-income countries. Four electronic databases (MEDLINE, EMBASE, CINAHL and Web of Science) were systematically searched from inception to October 2018 for population-based studies. We included studies reporting the prevalence of OA among people aged 15 years and over in low-income and lower middle-income countries. The prevalence estimates were pooled across studies using random effects meta-analysis. Our study was registered with PROSPERO, number CRD42018112870.The search identified 7414 articles, of which 356 articles were selected for full text assessment. 34 studies were eligible and included in the systematic review and meta-analysis. The pooled prevalence of OA was 16·05% (95% confidence interval (CI) 12·55–19·89), with studies demonstrating a substantial degree of heterogeneity (I2 = 99·50%). The pooled prevalence of OA was 16.4% (CI 11·60–21.78%) in South Asia, 15.7% (CI 5·31–30·25%) in East Asia and Pacific, and 14.2% (CI 7·95–21·89%) in Sub Saharan Africa. The meta-regression analysis showed that publication year, study sample size, risk of bias score and country-income categories were significantly associated with the variations in the prevalence estimates. The prevalence of OA is high in low-income and lower middle-income countries, with almost one in six of the study participants reported to have OA. With the changing population demographics and the shift to the emergence of non-communicable diseases, targeted public health strategies are urgently needed to address this growing epidemic in the aging population.


  • Open Access

    Individual and community-level socioeconomic position and its association with adolescents experience of childhood sexual abuse: a multilevel analysis of six countries in Sub-Saharan Africa

    by Ismail Yahaya, Antonio Ponce De Leon, Olalekan A. Uthman, Joaquim Soares, Gloria Macassa

    Childhood sexual abuse (CSA) is a substantial global health and human rights problem and consequently a growing concern in sub-Saharan Africa. We examined the association between individual and community-level socioeconomic status (SES) and the likelihood of reporting CSA. We applied multiple multilevel logistic regression analysis on Demographic and Health Survey data for 6,351 female adolescents between the ages of 15 and 18 years from six countries in sub-Saharan Africa, between 2006 and 2008. About 70% of the reported cases of CSA were between 14 and 17 years. Zambia had the highest proportion of reported cases of CSA (5.8%). At the individual and community level, we found that there was no association between CSA and socioeconomic position. This study provides evidence that the likelihood of reporting CSA cut across all individual SES as well as all community socioeconomic strata. We found no evidence of socioeconomic differentials in adolescents' experience of CSA, suggesting that adolescents from the six countries studied experienced CSA regardless of their individual- and community-level socioeconomic position. However, we found some evidence of geographical clustering, adolescents in the same community are subject to common contextual influences. Further studies are needed to explore possible effects of countries' political, social, economic, legal, and cultural impact on childhood sexual abuse.


  • Open Access

    Social disorganization and history of child sexual abuse against girls in sub-Saharan Africa: a multilevel analysis

    by Ismail Yahaya, Olalekan A Uthman, Joaquim Soares, Gloria Macassa

    Child sexual abuse (CSA) is a considerable public health problem. Less focus has been paid to the role of community level factors associated with CSA. The aim of this study was to examine the association between neighbourhood-level measures of social disorganization and CSA. We applied multiple multilevel logistic regression analysis on Demographic and Health Survey data for 6,351 adolescents from six countries in sub-Saharan Africa between 2006 and 2008. The percentage of adolescents that had experienced CSA ranged from 1.04% to 5.84%. There was a significant variation in the odds of reporting CSA across the communities, suggesting 18% of the variation in CSA could be attributed to community level factors. Respondents currently employed were more likely to have reported CSA than those who were unemployed (odds ratio [OR] = 2.05, 95% confidence interval [CI] 1.48 to 2.83). Respondents from communities with a high family disruption rate were 57% more likely to have reported CSA (OR=1.57, 95% CI 1.14 to 2.16). We found that exposure to CSA was associated with high community level of family disruption, thus suggesting that neighbourhoods may indeed have significant important effects on exposure to CSA. Further studies are needed to explore pathways that connect the individual and neighbourhood levels, that is, means through which deleterious neighbourhood effects are transmitted to individuals.


  • Interventions for HIV-associated nephropathy

    by Ismail Yahaya, Olalekan A Uthman, Muhammed Mubashir B Uthman

    Human immunodeficiency virus‐associated nephropathy (HIVAN) is the most common cause of end stage kidney disease (ESKD) in human immunodeficiency virus‐1 (HIV‐1) serotype patients and it mostly affects patients of African descent. It rapidly progresses to ESKD if untreated. The goal of treatment is directed toward reducing HIV‐1 replication and/or slowing the progression of chronic kidney disease. The following pharmacological agents have been used for the treatment of HIVAN: antiretroviral therapy, angiotensin‐converting enzyme inhibitors (ACEi), steroids and recently cyclosporin. Despite this, the effect of each intervention is yet to be evaluated. To evaluate the benefits and harms of adjunctive therapies in the management of HIVAN and its effects on symptom severity and all‐cause mortality. In January 2012 we searched the Cochrane Renal Group's Specialised Register, AIDS Education Global Information System (AEGIS database), ClinicalTrial.gov, the WHO International Clinical Trials Registry Portal, and reference lists of retrieved articles without language restrictions. In our original review we searched CENTRAL, MEDLINE, EMBASE, and AIDSearch, in addition to contacting individual researchers, research organisations and pharmaceutical companies. Randomised controlled trials (RCTs) and quasi‐RCTs of any therapy used in the treatment of HIVAN. We independently screened the search outputs for relevant studies and to retrieve full articles when necessary. For dichotomous outcomes results were to be expressed as risk ratios with 95% confidence intervals, and for continuous scales of measurement the mean difference was to be used. We identified four relevant ongoing studies: one is still ongoing; two have completed recruitment but are yet to be published; and the fourth study was suspended for unspecified reasons. No completed RCTs or quasi‐RCTs were identified. We summarised and tabulated the data from the observational studies, however no formal analyses were performed. There is currently no RCT‐based evidence upon which to base guidelines for the treatment of HIVAN, however three ongoing studies have been identified. Data from observational studies suggest steroids and angiotensin‐converting enzyme inhibitors appear to improve kidney function in patients with HIVAN, however no formal analyses were performed in this review. This review highlights the need for good quality RCTs to address the effects of interventions for treating this group. Interventions pour la néphropathie liée au VIH La néphropathie associée au VIH est la cause la plus courante dinsuffisance rénale terminale (IRT) chez les patients souffrant du VIH‐1. Elle affecte principalement les patients d'origine africaine. Elle évolue rapidement en IRT si elle n'est pas traitée. L'objectif du traitement est de réduire la multiplication virale du VIH‐1 et/ou de ralentir la progression de la maladie rénale chronique. Les agents pharmacologiques suivants ont été utilisés pour le traitement de la NLVIH : Un traitement antirétroviral, inhibiteurs de lenzyme de conversion de langiotensine (IECA), les stéroïdes et plus récemment, la cyclosporine. Malgré cela, l'effet de chaque intervention n'a pas encore être évalué. Évaluer les bénéfices et inconvénients des thérapies complémentaires pour la prise en charge de la NLVIH et ses effets sur la gravité des symptômes et la mortalité toutes causes confondues. En janvier 2012, nous avons effectué des recherches dans le registre spécialisé du Cochrane Renal Group, AIDS Education Global Information System (AEGIS base de données), ClinicalTrials.gov, WHO International Clinical Trials Registry Portal, et les références bibliographiques des articles extraits, sans restriction de langue. Dans notre revue initiale nous avons effectué des recherches dans CENTRAL, MEDLINE, EMBASE, et AIDSearch, en plus de prise de contact avec des chercheurs individuels, la recherche des organisations et des sociétés pharmaceutiques. Les essais contrôlés randomisés (ECR) et quasi‐ECR de toute thérapie utilisés dans le traitement de la NLVIH. Nous avons cherché dans les bases de données les études pertinentes et retrouvé le texte intégral, si besoin. Pour les résultats dichotomiques, les résultats étaient exprimés sous la forme de risques relatifs avec des intervalles de confiance à 95 % et, pour des échelles de mesure continues, la différence moyenne était de à être utilisés. Nous avons identifié quatre études pertinentes en cours : Une est toujours en cours ; deux études ont terminé le recrutement, mais ne sont pas encore publiées ; et la quatrième étude a été suspendue pour des raisons non spécifiées. Aucun ECR (ou quasi ECR) terminé na été identifiés. Nous avons résumé et compilés les données des études observationnelles, mais aucune qualification des analyses ont été réalisées. Il ny a actuellement aucune preuve fondée sur des ECR pour guider les recommandations concernant le traitement de la NLVIH, mais trois études en cours ont été identifiées. Les données issues d'études observationnelles suggèrent que les stéroïdes et les inhibiteurs de lenzyme de conversion de langiotensine semblent améliorer la fonction rénale chez les patients atteints de la NLVIH, mais ces analyses nont pas été effectuées dans cette revue. Cette revue souligne le besoin d'ECR de bonne qualité pour examiner les effets des interventions pour traiter ce groupe.


  • Interventions for HIV-associated nephropathy

    by Ismail Yahaya, Olalekan A Uthman, Muhammed Mubashir B Uthman

    Background Human immunodeficiency virus associated nephropathy (HIVAN) is the most common cause of end stage kidney disease (ESKD) in Human immunodeficiency virus‐1 (HIV‐1) serotype patients and it mostly affects patients of African descent. It rapidly progresses to ESKD if untreated. The goal of treatment is directed toward reducing HIV‐1 replication and/or slowing the progression of chronic kidney disease. The following pharmacological agents have been used for the treatment of HIVAN: antiretrovirals, angiotensin‐converting enzyme inhibitors (ACEi), steroids and recently cyclosporin. Despite this, the effect of each intervention is yet to be evaluated. Objectives To evaluate the benefits and harms of adjunctive therapies in the management of HIVAN and its effects on symptom severity and all‐cause mortality. Search methods We searched The Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Renal Group's specialised register, MEDLINE, EMBASE, AIDSearch, reference lists of articles and conference proceedings without language restrictions. We searched the international clinical trials registry platform search portal and also contacted individual researchers, research organisations and pharmaceutical companies that manufacture the drugs used for interventions. Selection criteria Randomised controlled trials (RCTs) and quasi‐RCTs of any therapy used in the treatment of HIVAN. Data collection and analysis We independently screened the search outputs for relevant studies and to retrieve full articles when necessary. We applied the inclusion criteria to identify four relevant ongoing studies, one is ongoing while the remaining two have completed recruitment and are yet to be published. The fourth study was suspended for an unknown reason. Main results No completed RCTs or quasi‐RCTs were identified to be included in the study. Authors' conclusions There is no RCT‐based evidence upon which to base guidelines for the treatment of HIVAN. However, steroids and ACEI appear to improve the kidney function of patients in the observational studies that were identified. This review highlights the need for good quality RCTs to address the effects of interventions for treating this group.


  • Open Access

    A population-based study of effect of multiple birth on infant mortality in Nigeria

    by Olalekan A Uthman, Mubashir B Uthman, Ismail Yahaya

    Multi-foetal pregnancies and multiple births including twins and higher order multiples births such as triplets and quadruplets are high-risk pregnancy and birth. These high-risk groups contribute to the higher rate of childhood mortality especially during early period of life. We examined the relationship between multiple births and infant mortality using univariable and multivariable survival regression procedure with Weibull hazard function, controlling for child's sex, birth order, prenatal care, delivery assistance; mother's age at child birth, nutritional status, education level; household living conditions and several other risk factors. Children born multiple births were more than twice as likely to die during infancy as infants born singleton (hazard ratio = 2.19; 95% confidence interval: 1.50, 3.19) holding other factors constant. Maternal education and household asset index were associated with lower risk of infant mortality. Multiple births are strongly negatively associated with infant survival in Nigeria independent of other risk factors. Mother's education played a protective role against infant death. This evidence suggests that improving maternal education may be key to improving child survival in Nigeria. A well-educated mother has a better chance of satisfying important factors that can improve infant survival: the quality of infant feeding, general care, household sanitation, and adequate use of preventive and curative health services.


  • Adjunctive therapies for HIV-associated nephropathy

    by Ismail Yahaya, Abdulrahman Olalekan Uthman, Muhammed Mubashir B Uthman